Overview page

Cyclobenzaprine is the active ingredient often known by the brand name Flexeril. It is a central nervous system agent prescribed to alleviate short-term muscle spasm in addition to the pain that accompanies it, typically as an adjunct to physical measures such as rest and physiotherapy.

Drug administration forms encountered internationally include immediate-release tablets (commonly 5 mg and 10 mg) and extended-release formulations (frequently 15 mg and 30 mg). Where this guide mentions 15 mg it usually refers to the extended-release strength unless stated otherwise.

Treatment with cyclobenzaprine is usually brief (often two to three weeks) and is intended to be used alongside non-drug treatments to help recovery from strains, sprains and other soft tissue injuries. For safety-related information see the health and safety measures to maintain safety and medical contrasignals pointing to sections below.

The Way It Works

Cyclobenzaprine reduces excessive muscle tightness by influencing neural circuits in the brainstem and spinal cord. It does not act directly on muscle fibers; instead it modulates reflex pathways that contribute to involuntary muscle contraction.

Dosing and Instructions

Follow the prescription and instructions provided by your clinician. The usual course is short and reassessment is recommended if symptoms persist.

• Extended-release 15 mg tablets are generally taken once daily.
• Immediate-release tablets (5 mg or 10 mg) can be split across the day according to the prescribing facts and figures.
• Keep dosing intervals consistent to preserve a steady therapeutic effect.
• Never increase the dose or prolong the course without consulting your prescriber.

If there is no improvement after the initial short course, contact the clinician who prescribed the medicine for review again and a further option strategies.

Safety care steps and Safety

• Inform your prescriber if you have liver disease, glaucoma, prostate enlargement, difficulty voiding, or thyroid problems.
• Older adults are more susceptible to sedation, dizziness and confusion; clinicians often choose lower doses or other therapies for elderly patients.
• Data on use in pregnancy and lactation are limited. Discuss potential benefits and risks with your healthcare professional if you are pregnant, planning pregnancy or breastfeeding.
• Cyclobenzaprine commonly causes drowsiness. Do not drive, operate heavy machinery or perform tasks requiring full alertness until you know how it affects you.
• Be vigilant for signs of serotonin syndrome when combining cyclobenzaprine with serotonergic drugs. Glance at the risks and cautions issued related to long term effects area for symptom details.

Situations in which this treatment is not advised

• Recent myocardial infarction, severe congestive heart failure, or significant arrhythmias or conduction block.
• Uncontrolled hyperthyroidism or severe thyroid disorders.
• Use of monoamine oxidase inhibitors (MAOIs) currently or within the previous 14 days is contraindicated because of the risk of severe and possibly life-threatening reactions.

Notices of warning and Secondary reactions

Seek immediate medical assistance if you experience any signs of an allergic reaction, such as hives, swelling of the face, lips, tongue or throat, or difficulty breathing.

Stop the medicine and obtain urgent evaluation for new onset chest pain, palpitations, sudden weakness or numbness, slurred speech, or a marked loss of coordination.

Serotonin syndrome is a serious condition that may occur when cyclobenzaprine is combined with other serotonergic medicines. Symptoms can include agitation, hallucinations, high temperature, sweating, tremor, rigidity, rapid heart rate, nausea and vomiting. Emergency care is required if these signs develop.

Milder, more common adverse sequelae include drowsiness, fatigue, head discomfort, dizziness, dry mouth, nausea and constipation.

Drug Interaction Prevention

Cyclobenzaprine may increase sedation when taken with other central nervous system depressants. Always review your complete medication list, including over-the-counter products and supplements, with your prescriber or pharmacist before starting this medicine.

• Opioids, benzodiazepines, sedative-hypnotics and other muscle relaxants can potentiate drowsiness and increase the risk of respiratory depression.
• Concurrent use with serotonergic agents (SSRIs, SNRIs, tramadol, some antiemetics, certain Parkinson medications) raises the risk of serotonin syndrome.
• Anticholinergic drugs (some antihistamines, medications for overactive bladder) can worsen dry mouth, constipation and confusion.
• Interactions among users have been reported with bupropion, meperidine and some calcium channel blockers such as verapamil.
• Avoid alcohol while using cyclobenzaprine because it magnifies sedation and impairs coordination.

Skipped dose

If you forget about a dose, take it as soon as you remember unless it is near the time for your next scheduled dose. Do not stack two doses to compensate for a i did not take my prescribed dose. Continue with your regular dosing schedule.

Overdose incident

Symptoms of non fatal overdose may include extreme drowsiness, vomiting, irregular or rapid heartbeat, tremor, agitation or hallucinations. Overdose tragedy can pose a threat to life. Contact emergency services or your local poisons information service immediately if non fatal overdose is suspected.

Tips for Storing

• Ensure medicines are kept out of reach and sight of children and pets.
• Store in a well-closed container at room temperature, ideally between 15 to 30 C (59 to 86 F).
• Do not use after the expiry date and dispose of unwanted or expired medication safely per local guidelines.

Other Options for Similar Medications

When cyclobenzaprine is unsuitable or unavailable, prescribers may suggest other medicines or non-pharmacological approaches. Well-known variant options in Australia include:

• Baclofen (oral) — widely used for spasticity and sometimes for acute muscle spasm; often available and frequently subsidised through the PBS for eligible markers that point to.
• Tizanidine in pharmacology — an alpha-2 adrenergic agonist muscle relaxant that can cause sedation and low blood pressure in some patients.
• Diazepam — a benzodiazepine with muscle-relaxant effects; short-term use only because of tolerance and dependence risks.
• Orphenadrine — an anticholinergic antispasmodic with anticholinergic treatment side effects to consider.
• Methocarbamol and metaxalone — additional centrally acting muscle relaxants with varying availability and regulatory status between countries.

Non-drug strategies such as targeted exercise, heat/cold therapy, manual therapy and physiotherapy often reduce the need for medication and are an important part of recovery.

Place them in comparison estimated costs in the price catalog guide section and examine access options in the legal recognition status with access provisions the document section.

Australian market prices priced in AUD

Prices vary depending on source, pack size, and whether a product is subsidised under the Pharmaceutical Benefits Scheme (PBS). Figures below are indicative and are provided as a general reference only.

• Cyclobenzaprine (Flexeril) — Not commonly marketed located within Australia. If imported or purchased from overseas suppliers, expect private costs in the order of about AUD 0.80 to AUD 2.50 per 10 to 15 mg tablet before freight and handling. Shipping and pharmacy fees can add around AUD 10 to AUD 25 or more.
• Baclofen (generic) — Generally available and often PBS-subsidised for some indicators of. Private cost for 100 x ten milligram dosage tablets might be about AUD 10 to AUD 25. PBS co-payment for general patients is typically around AUD 30 to AUD 32 per prescription; concession rates are lower.
• Diazepam (generic) — Typically inexpensive; private packs commonly cost between AUD 5 and AUD 15, with PBS rules applying where relevant.
• Tizanidine in pharmacology — Private prices vary by supplier and strength, roughly AUD 15 to AUD 40 for common pack sizes; PBS coverage is not universal for all strengths or evidence.

Your actual out-of-pocket cost depends on the pharmacy, your location, PBS eligibility, private insurance coverage and any importation charges. Obtain professional input your pharmacist for current prices and options.

For patients considering importation, be aware that additional customs duties and postal fees may apply and that product quality and regulatory approval differ between jurisdictions.

Status of legal recognition and service access in Australia

Summary: Cyclobenzaprine is not widely sold in the Commonwealth of Australia. When it is supplied it is treated as a prescription-only medicine and falls under Therapeutic Goods Administration (TGA) oversight.

• Prescription-only medicine (Schedule 4): If supplied, cyclobenzaprine requires a valid prescription and clinical supervision.
• Special Access Scheme (SAS Category B): Prescribers can request patient-specific access to unapproved medicines when clinically justified.
• Authorised Prescriber pathway: Clinicians may obtain authorisation to prescribe certain unapproved medicines to defined patient groups.
• Personal importation: Individuals may import limited supplies (commonly up to three months) of prescription medicines for personal use if they hold a valid prescription and meet Customs and TGA rules; documentation and correct packaging are required and some products may be restricted.

Because cyclobenzaprine is generally not listed on the PBS in Australia, government subsidy is unlikely and patients should expect to pay privately or use an approved pathway. Driving and workplace safety rules prohibit performing safety-sensitive tasks while impaired; sedating medicines such as cyclobenzaprine can affect fitness for such activities.

This page is a general summary and not legal advice. For the latest regulatory information consult the TGA website, your prescriber or your pharmacist.

Brief Facts

• Indication: short-term treatment of acute skeletal muscle spasm with associated pain.
• Typical treatment length: commonly restricted to two to three weeks.
• Main cautions: sedation, anticholinergic effects such as dry mouth and constipation, and serious real time interacting with otherss enable quick problem solving. with MAOIs and other serotonergic agents.
• Cast a glance at the personal interactions build trust and rapport. between medications and warning bulletins and potential for growth negative effects the sections contain more detail.

Back to at the top